RhumbLine Advisers
VIR icon

RhumbLine Advisers’s Vir Biotechnology VIR Stock Holding History

RhumbLine Advisers’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.91M Buy
285,154
+52,604
+23% +$500K ﹤0.01% 1749
2026
Q1 		$2.08M Buy
232,550
+24,191
+12% +$193K ﹤0.01% 1836
2025
Q4 		$1.26M Sell
208,359
-18,440
-8% -$110K ﹤0.01% 2115
2025
Q3 		$1.3M Sell
226,799
-2,150
-0.9% -$11K ﹤0.01% 2114
2025
Q2 		$1.15M Buy
228,949
+2,300
+1% +$12.3K ﹤0.01% 2171
2025
Q1 		$1.47M Sell
226,649
-10,032
-4% -$89.2K ﹤0.01% 1972
2024
Q4 		$1.74M Buy
236,681
+1,288
+0.5% +$10.2K ﹤0.01% 1964
2024
Q3 		$1.76M Sell
235,393
-3,111
-1% -$27K ﹤0.01% 1979
2024
Q2 		$2.12M Buy
238,504
+9,817
+4% +$94.1K ﹤0.01% 1852
2024
Q1 		$2.32M Sell
228,687
-46,771
-17% -$476K ﹤0.01% 1833
2023
Q4 		$2.77M Buy
275,458
+13,471
+5% +$123K ﹤0.01% 1741
2023
Q3 		$2.45M Buy
261,987
+14,374
+6% +$205K ﹤0.01% 1758
2023
Q2 		$6.07M Buy
247,613
+12,225
+5% +$307K 0.01% 1267
2023
Q1 		$5.48M Buy
235,388
+14,666
+7% +$375K 0.01% 1261
2022
Q4 		$5.59M Sell
220,722
-1,645
-0.7% -$40.3K 0.01% 1220
2022
Q3 		$4.29M Buy
222,367
+7,561
+4% +$192K 0.01% 1329
2022
Q2 		$5.47M Buy
214,806
+150,037
+232% +$3.5M 0.01% 1194
2022
Q1 		$1.67M Buy
64,769
+915
+1% +$27.1K ﹤0.01% 1906
2021
Q4 		$2.67M Sell
63,854
-480
-0.7% -$18.8K ﹤0.01% 1727
2021
Q3 		$2.8M Buy
64,334
+1,383
+2% +$59.9K ﹤0.01% 1702
2021
Q2 		$2.98M Buy
62,951
+2,566
+4% +$117K ﹤0.01% 1736
2021
Q1 		$3.1M Sell
60,385
-5,050
-8% -$272K ﹤0.01% 1676
2020
Q4 		$1.75M Buy
65,435
+4,307
+7% +$140K ﹤0.01% 1914
2020
Q3 		$2.1M Sell
61,128
-7,679
-11% -$331K ﹤0.01% 1657
2020
Q2 		$2.82M Buy
68,807
+58,253
+552% +$1.96M ﹤0.01% 1539
2020
Q1 		$362K Buy
+10,554
New +$284K ﹤0.01% 2314

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

RhumbLine Advisers's VIR Position: Q2 2026 in Review

RhumbLine Advisers increased its Vir Biotechnology (VIR) stake by 23% in Q2 2026, buying an estimated $500K and bringing the position to 285,154 shares worth $2.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1749.

RhumbLine Advisers first reported a position in VIR in Q1 2020 and has held it in 26 quarters since. The position peaked at $6.07M in Q2 2023. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • RhumbLine Advisers held 285,154 shares of Vir Biotechnology worth $2.91M as of Q2 2026.
  • RhumbLine Advisers bought 52,604 Vir Biotechnology shares in Q2 2026, an estimated $500K.
  • Vir Biotechnology made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1749 holding.
  • RhumbLine Advisers first reported a position in Vir Biotechnology in Q1 2020 and has held it in 26 quarters since.
  • RhumbLine Advisers's Vir Biotechnology position peaked at $6.07M in Q2 2023.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.